1️⃣ Momentum + Real Figures
Aaj (11 November 2025) Poly Medicure ne intraday me zabardast performance dikhaya — share price ₹2,070.60 tak upar gaya, matlab +₹208.30 / +11.19% jump (Groww data). Market ne is stock ko top gainer treat kiya. Ye move sirf random spike nahi tha — company ke Q2 results, acquisition updates, aur ESOP announcements ke combo se trigger hua.
Poly Medicure Q2 FY2026 Results — Full Breakdown
The Q2 FY2026 results were the primary catalyst for the 11.19% single-day rally. Revenue growth, expanding international presence, and strategic acquisitions all came together in one announcement — a rare combination that gives institutional investors strong reasons to buy.
| Metric | Q2 FY2025 | Q2 FY2026 | Change |
|---|---|---|---|
| Net Profit | Rs 780M | Rs 918M | +17.7% |
| Revenue | Rs 3.8B | Rs 4.2B | +10.5% |
| Operating Margin | 27.4% | 25.8% | −160bps |
| Debt-to-Equity | 0.10 | 0.08 | Improved |
Italy Expansion — The Medistream Acquisition
On the same day as the Q2 results, Poly Medicure confirmed completion of its acquisition of Medistream, an Italian medical device distributor. Alongside this, the company announced a proposal from the Citieffe Group worth EUR 18.8 million — signalling strong European demand for Indian medical devices.
Italy and Germany together represent one of the largest medical consumables markets in the EU. Having a local distribution entity removes regulatory and logistics friction that typically slows Indian MedTech companies in European markets. This gives Poly Medicure a structural revenue advantage over domestic-only competitors.
ESOP Allotment — Why It Matters
The ESOP allotment announced the same day was a small but important signal. When employees exercise options at market price, it shows insiders are bullish on near-term performance. Combined with promoter holding remaining stable above 55%, there is no dilution concern for retail investors.
Valuation — Is Poly Medicure Still Worth Buying?
- P/E Ratio: 52.12x — premium valuation reflecting growth expectations
- Debt-to-Equity: 0.08 — almost zero debt, strong balance sheet
- Promoter Holding: Stable above 55% — no dilution concern
- Key risk: Operating margin compression from 27.4% to 25.8% needs to reverse in Q3 for valuation to hold
What Investors Should Watch Next
The critical variable is whether operating margins recover in Q3 FY2026. The Italy acquisition adds revenue but also integration costs in the short term. If margins return above 27% in the next quarterly result, the P/E of 52x becomes easier to justify. If margins fall further, the stock could give back part of the rally. Track Q3 results date and keep an eye on European sales contribution in the next earnings release.